Multiple sclerosis (MS) is a chronic demyelinating disease which is considered to be an autoimmune disease impacting the central nervous system (CNS). Patients with MS may have certain orofacial manifestations and oral microbiological changes as a result of different treatment modalities. Thus, this study aimed to investigate the changes of Candida Albicans in normal oral flora during different...

multiple sclerosis (ms) is a chronic inflammatory disease characterized by central nervous system (cns) lesions that can lead to severe physical or cognitive disability as well as neurological defects. although the etiology and pathogenesis of ms remains unclear, the present documents illustrate that the cause of ms is multifactorial and include genetic predisposition together with environmenta...

multiple sclerosis (ms) is a neuroinflammatory autoimmune disease which mediated by various molecular and cellular immune components however recent reports have shown that coagulation factors that traditionally separate from the immune system might also be involved in ms development and progression.studies on experimental autoimmune encephalomyelitis (eae) and human ms patients reports alterati...

OBJECTIVE To study the therapeutic effects of low-dose amiodarone and Betaloc on hypertrophic cardiomyopathy complicated by malignant ventricular arrhythmias. METHODS Eighty-two such patients were selected and divided into a treatment group and a control group by the random number method (n=41), which were administered with low-dose amiodarone plus Betaloc and individual Betaloc respectively....

BACKGROUND Fingolimod is the first oral disease-modifying therapy indicated for the treatment of patients with relapsing forms of multiple sclerosis (MS) to reduce the frequency of clinical relapses and delay the progression of physical disability caused by MS. OBJECTIVE To obtain data from MS patients who have taken fingolimod regarding their treatment choice, first-dose observation (FDO) ex...

BACKGROUND The Danish Multiple Sclerosis Society initiated a large-scale bridge building and integrative treatment project to take place from 2004-2010 at a specialized Multiple Sclerosis (MS) hospital. In this project, a team of five conventional health care practitioners and five alternative practitioners was set up to work together in developing and offering individualized treatments to 200 ...

The likely pathogenic mechanisms of multiple sclerosis (MS) provide a sound rationale for investigating the efficacy of drugs possessing immunosuppressive or immunomodulatory properties. With proven efficacy, safety and tolerability, interferon beta formulations and glatiramer acetate have become the mainstay of initial treatment for patients with relapsing forms of MS. More recently, natalizum...

OBJECTIVE To summarize the conclusions of an expert panel of neurologists specializing in multiple sclerosis (MS) convened for the purpose of creating a treatment algorithm with regard to the clinical management of MS. The panel was sponsored by the Health Science Center for Continuing Medical Education and the University of Medicine and Dentistry of New Jersey and supported by an educational g...

introduction: multiple sclerosis (ms) and its animal model, experimental autoimmune encephalomyelitis (eae), is a chronic inflammatory diseases and degenerative myelin in the cns. with respect to being the main cause of this disease is unknown; the most common treatments for the disease (ms) with the aim of suppressing harmful inflammatory responses are used. neuro transmitters having immunosup...

Multiple sclerosis (MS) is a chronic, autoimmune, inflammatory, demyelinating disease of the central nervous system. MS is increasingly recognized in the pediatric population, and it is usually diagnosed around 15 years of age. The exact etiology of MS is still not known, although autoimmune, genetic, and environmental factors play important roles in its development, making it a multifactorial ...